{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:00:36Z","timestamp":1790870436057,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"DOI":"10.1186\/s12872-026-06113-z","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T09:26:10Z","timestamp":1781083570000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Vutrisiran in transthyretin amyloid cardiomyopathy: a structured review of the HELIOS-B trial and its secondary analyses"],"prefix":"10.1186","volume":"26","author":[{"given":"Ahsanullah","family":"Niazai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bakht Muhammad","family":"Zurmati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Tayyab","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulmadin","family":"Hikmat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hafiz Umar","family":"Sohaib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hafiza Hooria","family":"Zainab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Jawad Khan","family":"Faridzai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mah Rukh","family":"Nisar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"6113_CR1","doi-asserted-by":"crossref","unstructured":"Cynthia Bither ACNPAACMFMPMSMMSDSMJGMPSBPEAMSEMPPJMP. Impact of Vutrisiran on Outpatient Worsening Heart Failure in Patients with Transthyretin Amyloidosis with Cardiomyopathy in the HELIOS-B Trial. Heart & Lung; 2025.","DOI":"10.1016\/j.hrtlng.2025.04.012"},{"key":"6113_CR2","doi-asserted-by":"publisher","first-page":"iii19","DOI":"10.1093\/eurheartjsupp\/suaf009","volume":"27","author":"E Biagini","year":"2025","unstructured":"Biagini E, Longhi S. More players in the treatment of transthyretin amyloidosis? The HELIOS-B study. Eur Heart J Supplement. 2025;27:iii19\u201321. https:\/\/doi.org\/10.1093\/eurheartjsupp\/suaf009.","journal-title":"Eur Heart J Supplement"},{"key":"6113_CR3","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1093\/eurheartj\/ehad357","volume":"44","author":"RK Cheng","year":"2023","unstructured":"Cheng RK, Cuddy SAM. Neurohormonal blockade in transthyretin amyloidosis: perhaps one size does not fit all? Eur Heart J. 2023;44:2908\u201310. https:\/\/doi.org\/10.1093\/eurheartj\/ehad357.","journal-title":"Eur Heart J"},{"key":"6113_CR4","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehad347","volume":"44","author":"A Ioannou","year":"2023","unstructured":"Ioannou A, Massa P, Patel RK, Razvi Y, Porcari A, Rauf MU, et al. Conventional heart failure therapy in cardiac ATTR amyloidosis. Eur Heart J. 2023;44:2893\u2013907. https:\/\/doi.org\/10.1093\/eurheartj\/ehad347.","journal-title":"Eur Heart J"},{"key":"6113_CR5","doi-asserted-by":"publisher","first-page":"I131","DOI":"10.1093\/eurheartjsupp\/suac104","volume":"24","author":"A Cantone","year":"2022","unstructured":"Cantone A, Sanguettoli F, Passo BD, Serenelli M, Rapezzi C. The treatment of amyloidosis is being refined. Eur Heart J Supplement. 2022;24:I131\u20138. https:\/\/doi.org\/10.1093\/eurheartjsupp\/suac104.","journal-title":"Eur Heart J Supplement"},{"key":"6113_CR6","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/nejmoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018;379:1007\u201316. https:\/\/doi.org\/10.1056\/nejmoa1805689.","journal-title":"N Engl J Med"},{"key":"6113_CR7","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/nejmoa2305434","volume":"390","author":"JD Gillmore","year":"2024","unstructured":"Gillmore JD, Judge DP, Cappelli F, Fontana M, Garcia-Pavia P, Gibbs S, et al. Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2024;390:132\u201342. https:\/\/doi.org\/10.1056\/nejmoa2305434.","journal-title":"N Engl J Med"},{"key":"6113_CR8","doi-asserted-by":"publisher","unstructured":"Dave P, Anand P, Kothawala A, Srikaram P, Shastri D, Uddin A et al. RNA Interference Therapeutics for Hereditary Amyloidosis: A Narrative Review of Clinical Trial Outcomes and Future Directions. Cureus. 2024. https:\/\/doi.org\/10.7759\/cureus.62981","DOI":"10.7759\/cureus.62981"},{"key":"6113_CR9","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","volume":"139","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, Adams D, Kristen A, Grogan M, Gonz\u00e1lez-Duarte A, Maurer MS, et al. Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients with Hereditary Transthyretin-Mediated Amyloidosis: Analysis of the APOLLO Study. Circulation. 2019;139:431\u201343. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.035831.","journal-title":"Circulation"},{"key":"6113_CR10","doi-asserted-by":"crossref","unstructured":"Pablo Garcia-Pavia 1 RW 2, CM. HK 5,. HELIOS-B: 12-Month Results From The Open-Label Extension Period Of Vutrisiran In Patients With Transthyretin Amyloidosis With Cardiomyopathy. Volume 3. J Card Fail; 2026. DD 4.","DOI":"10.1016\/j.cardfail.2025.11.031"},{"key":"6113_CR11","doi-asserted-by":"crossref","unstructured":"Garcia-Pavia P, Witteles R, Morbach C, Delgado D, Kitaoka H, Maurer M et al. HELIOS-B: 12-month results from the open-label extension period of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. 2025.","DOI":"10.1093\/eurheartj\/ehaf784.1222"},{"key":"6113_CR12","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.jacbts.2024.07.005","volume":"9","author":"M Fontana","year":"2024","unstructured":"Fontana M, Gillmore JD, Verona G. Large Transthyretin Aggregates in Plasma of ATTR Amyloidosis Patients: Future Clinical Implications. JACC Basic Transl Sci. 2024;9:1101\u20133. https:\/\/doi.org\/10.1016\/j.jacbts.2024.07.005.","journal-title":"JACC Basic Transl Sci"},{"key":"6113_CR13","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.jacc.2024.11.015","volume":"85","author":"M Fontana","year":"2025","unstructured":"Fontana M, Maurer MS, Gillmore JD, Bender S, Aldinc E, Eraly SA, et al. Outpatient Worsening Heart Failure in Patients With Transthyretin Amyloidosis With Cardiomyopathy in the HELIOS-B Trial. J Am Coll Cardiol. 2025;85:753\u201361. https:\/\/doi.org\/10.1016\/j.jacc.2024.11.015.","journal-title":"J Am Coll Cardiol"},{"key":"6113_CR14","doi-asserted-by":"crossref","unstructured":"Sheikh FHOBDCF aus dem SFCSJGESCJG. Efficacy Of Vutrisiran In Patients With Transthyretin Amyloidosis With Cardiomyopathy By Baseline Health Status And Quality Of Life. J Card Fail; 2026.","DOI":"10.1016\/j.cardfail.2025.11.129"},{"key":"6113_CR15","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/j.jacc.2025.03.477","volume":"85","author":"MS Maurer","year":"2025","unstructured":"Maurer MS, Witteles RM, Garcia-Pavia P, Sheikh FH, Morbach C, Rodriguez Duque D, et al. Impact of Heart Failure Severity on Vutrisiran Efficacy in Transthyretin Amyloidosis With Cardiomyopathy. J Am Coll Cardiol. 2025;85:1927\u201339. https:\/\/doi.org\/10.1016\/j.jacc.2025.03.477.","journal-title":"J Am Coll Cardiol"},{"key":"6113_CR16","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1016\/j.jacc.2025.04.008","volume":"85","author":"RM Witteles","year":"2025","unstructured":"Witteles RM, Garcia-Pavia P, Damy T, Grogan M, Sheikh FH, Morbach C, et al. Vutrisiran Improves Survival and Reduces Cardiovascular Events in ATTR Amyloid Cardiomyopathy: HELIOS-B. J Am Coll Cardiol. 2025;85:1959\u201370. https:\/\/doi.org\/10.1016\/j.jacc.2025.04.008.","journal-title":"J Am Coll Cardiol"},{"key":"6113_CR17","doi-asserted-by":"publisher","first-page":"3560","DOI":"10.1038\/s41591-025-03851-z","volume":"31","author":"KS Jering","year":"2025","unstructured":"Jering KS, Fontana M, Lairez O, Longhi S, Azevedo O, Morbach C, et al. Effects of vutrisiran on cardiac structure and function in patients with transthyretin amyloidosis with cardiomyopathy: secondary outcomes of the HELIOS-B trial. Nat Med. 2025;31:3560\u20138. https:\/\/doi.org\/10.1038\/s41591-025-03851-z.","journal-title":"Nat Med"},{"key":"6113_CR18","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.jacc.2025.06.022","volume":"86","author":"KS Jering","year":"2025","unstructured":"Jering KS, Fontana M, Skali H, Bulwer BE, Prasad N, Roshanali F, et al. Effects of Vutrisiran on Cardiac Function and Outcomes in Patients With Transthyretin Amyloidosis With Cardiomyopathy. J Am Coll Cardiol. 2025;86:444\u201355. https:\/\/doi.org\/10.1016\/j.jacc.2025.06.022.","journal-title":"J Am Coll Cardiol"},{"key":"6113_CR19","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.jacc.2025.04.055","volume":"86","author":"MS Maurer","year":"2025","unstructured":"Maurer MS, Berk JL, Damy T, Sheikh FH, Gonz\u00e1lez-Costello J, Morbach C, et al. Impact of Vutrisiran on Cardiac Biomarkers in Patients With Transthyretin Amyloidosis With Cardiomyopathy From HELIOS-B. J Am Coll Cardiol. 2025;86:459\u201375. https:\/\/doi.org\/10.1016\/j.jacc.2025.04.055.","journal-title":"J Am Coll Cardiol"},{"key":"6113_CR20","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021;372. https:\/\/doi.org\/10.1136\/bmj.n71","DOI":"10.1136\/bmj.n71"},{"key":"6113_CR21","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2409134","volume":"392","author":"M Fontana","year":"2025","unstructured":"Fontana M, Berk JL, Gillmore JD, Witteles RM, Grogan M, Drachman B, et al. Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy. N Engl J Med. 2025;392:33\u201344. https:\/\/doi.org\/10.1056\/NEJMoa2409134.","journal-title":"N Engl J Med"},{"key":"6113_CR22","doi-asserted-by":"publisher","unstructured":"Witteles RM, Garcia-Pavia P, Morbach C, Gillmore JD, Taylor MS, Concei\u00e7\u00e3o I et al. Vutrisiran in Transthyretin Amyloidosis: A Pooled Safety Analysis of HELIOS-A and HELIOS-B. JACC: Advances 2025;4. https:\/\/doi.org\/10.1016\/j.jacadv.2025.102066","DOI":"10.1016\/j.jacadv.2025.102066"},{"key":"6113_CR23","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1016\/j.jacc.2025.03.454","volume":"85","author":"FH Sheikh","year":"2025","unstructured":"Sheikh FH, Habib G, Tang WHW, Gillmore JD, Egolum UO, Longhi S, et al. Impact of Vutrisiran on Functional Capacity and Quality of Life in Transthyretin Amyloidosis With Cardiomyopathy. J Am Coll Cardiol. 2025;85:1943\u201355. https:\/\/doi.org\/10.1016\/j.jacc.2025.03.454.","journal-title":"J Am Coll Cardiol"},{"key":"6113_CR24","doi-asserted-by":"crossref","unstructured":"Yilmaz AL-Balnkhaeddbshm. Vutrisiran reduces days lost to death and\/or hospitalization versus placebo in patients with transthyretin amyloidosis with cardiomyopathy in the HELIOS-B trial. Eur Heart J 2025.","DOI":"10.1093\/eurheartj\/ehaf784.1256"},{"key":"6113_CR25","doi-asserted-by":"publisher","first-page":"3579","DOI":"10.1016\/s0735-1097(20)34206-6","volume":"75","author":"R Shilling","year":"2020","unstructured":"Shilling R, Karsten V, Silliman N, Chen J, Li W, Vest J, STUDY DESIGN AND RATIONALE OF HELIOS-B:, A PHASE 3 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF VUTRISIRAN IN PATIENTS WITH ATTR AMYLOIDOSIS WITH CARDIOMYOPATHY. J Am Coll Cardiol. 2020;75:3579. https:\/\/doi.org\/10.1016\/s0735-1097(20)34206-6.","journal-title":"J Am Coll Cardiol"},{"key":"6113_CR26","doi-asserted-by":"crossref","unstructured":"Sheikh Fdjfmavg-Ppkmj-Dabyzhes. Vutrisiran Improved Outcomes Versus Placebo in Patients with Transthyretin Amyloidosis with Cardiomyopathy and Severe Chronic Kidney Disease. Post Hoc Analysis of HELIOS-B. Circulation; 2025.","DOI":"10.1161\/circ.152.suppl_3.4362795"},{"key":"6113_CR27","doi-asserted-by":"crossref","unstructured":"Sheikh Fdjfmavg-Ppkmj-Dabyzhes. Vutrisiran Improved Outcomes Versus Placebo in Patients with Transthyretin Amyloidosis with Cardiomyopathy and Severe Chronic Kidney Disease. Post Hoc Analysis of HELIOS-B. Circulation; 2025.","DOI":"10.1161\/circ.152.suppl_3.4362795"},{"key":"6113_CR28","doi-asserted-by":"crossref","unstructured":"Siddiqi Okrflgdm. Impact of Vutrisiran on Functional Capacity and Quality of Life in ATTR Cardiomyopathy: HELIOS-B Analysis. J Am Coll Cardiol 2025.","DOI":"10.1016\/j.jacc.2025.03.537"},{"key":"6113_CR29","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1038\/s44161-025-00736-9","volume":"4","author":"G Schwaerzer","year":"2025","unstructured":"Schwaerzer G. Vutrisiran improves cardiac structure and function in individuals with transthyretin amyloidosis with cardiomyopathy. Nat Cardiovasc Res. 2025;4:1210\u20131210. https:\/\/doi.org\/10.1038\/s44161-025-00736-9.","journal-title":"Nat Cardiovasc Res"},{"issue":"1","key":"6113_CR30","doi-asserted-by":"publisher","first-page":"102883","DOI":"10.1016\/j.cpcardiol.2024.102883","volume":"50","author":"A Albulushi","year":"2025","unstructured":"Albulushi A, Buraiki JA, Aly G, Al-Wahshi Y, Jahangirifard A. Role of biomarkers in early diagnosis and prognosis of cardiac amyloidosis: A systematic review and meta-analysis. Curr Probl Cardiol. 2025;50(1):102883. https:\/\/doi.org\/10.1016\/j.cpcardiol.2024.102883 . Epub 2024 Oct 28. PMID: 39490645.","journal-title":"Curr Probl Cardiol"},{"key":"6113_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40120-016-0040-x","volume":"5","author":"T Coelho","year":"2016","unstructured":"Coelho T, Merlini G, Bulawa CE, et al. Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis. Neurol Ther. 2016;5:1\u201325. https:\/\/doi.org\/10.1007\/s40120-016-0040-x.","journal-title":"Neurol Ther"},{"issue":"17","key":"6113_CR32","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","volume":"389","author":"MS Maurer","year":"2023","unstructured":"Maurer MS, Kale P, Fontana M, Berk JL, Grogan M, Gustafsson F, Hung RR, Gottlieb RL, Damy T, Gonz\u00e1lez-Duarte A, Sarswat N, Sekijima Y, Tahara N, Taylor MS, Kubanek M, Donal E, Palecek T, Tsujita K, Tang WHW, Yu WC, Obici L, Sim\u00f5es M, Fernandes F, Poulsen SH, Diemberger I, Perfetto F, Solomon SD, Di Carli M, Badri P, White MT, Chen J, Yureneva E, Sweetser MT, Jay PY, Garg PP, Vest J, Gillmore JD. APOLLO-B Trial Investigators. Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis. N Engl J Med. 2023;389(17):1553\u201365. https:\/\/doi.org\/10.1056\/NEJMoa2300757 . PMID: 37888916; PMCID: PMC10757426.","journal-title":"N Engl J Med"},{"issue":"6","key":"6113_CR33","doi-asserted-by":"publisher","first-page":"oeaf147","DOI":"10.1093\/ehjopen\/oeaf147","volume":"5","author":"A Aimo","year":"2025","unstructured":"Aimo A, Castiglione V, Emdin M, Lorenzoni V, Vergaro G. Relative efficacy of tafamidis, acoramidis, patisiran and vutrisiran in patients with transthyretin cardiac amyloidosis: a network meta-analysis. Eur Heart J Open. 2025;5(6):oeaf147. https:\/\/doi.org\/10.1093\/ehjopen\/oeaf147 . PMID: 41282536; PMCID: PMC12637029.","journal-title":"Eur Heart J Open"},{"issue":"9","key":"6113_CR34","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1002\/ejhf.3339","volume":"26","author":"SA Muller","year":"2024","unstructured":"Muller SA, Peir\u00f3-Aventin B, Biagioni G, Tini G, Saturi G, Kronberger C, Achten A, Dobner S, Te Rijdt WP, Gasperetti A, Te Riele ASJM, Varr\u00e0 GG, Ponziani A, Hirsch A, Porcari A, van der Meer MG, Zampieri M, van der Harst P, Kammerlander A, Biagini E, van Tintelen JP, Barbato E, Asselbergs FW, Menale S, Gr\u00e4ni C, Merlo M, Michels M, Knackstedt C, Nitsche C, Longhi S, Musumeci B, Cappelli F, Garcia-Pavia P, Oerlemans MIFJ. Evaluation of the 2021 ESC recommendations for family screening in hereditary transthyretin cardiac amyloidosis. Eur J Heart Fail. 2024;26(9):2025\u201334. https:\/\/doi.org\/10.1002\/ejhf.3339 . Epub 2024 Jun 17. PMID: 38887861.","journal-title":"Eur J Heart Fail"},{"key":"6113_CR35","doi-asserted-by":"publisher","unstructured":"Cappelli F, Fumagalli C, Luigetti M, Mussinelli R, Longhi S, Guaraldi P, Aimo A, Argir\u00f2 A, Barilaro A, Biagini E, Biagioni G, Ceccanti M, Cipriani A, Chimenti C, De Michieli L, Di Bella G, Emdin M, Graziani F, Imazio M, Limongelli G, Lofiego C, Musca F, Ossola P, Nuvolone M, Perlini S, Pieroni M, Porcari A, Musumeci B, Palmiero G, Perfetto F, Ruotolo I, Russo M, Tini G, Vergaro G, Vagnarelli F, Verrillo F, Sciarrone MA, Salvalaggio A, Zampieri M, Mazzoni C, Sinagra G, Palladini G, Merlo M, Obici L. Cascade genetic screening in families with hereditary transthyretin amyloidosis: diagnostic and prognostic impact. Eur Heart J 2026 Apr 7:ehag222. https:\/\/doi.org\/10.1093\/eurheartj\/ehag222. Epub ahead of print. PMID: 41955077.","DOI":"10.1093\/eurheartj\/ehag222"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-026-06113-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-06113-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-06113-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:23:45Z","timestamp":1785767025000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12872-026-06113-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6113"],"URL":"https:\/\/doi.org\/10.1186\/s12872-026-06113-z","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"19 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. This study is a systematic review of previously published data and did not involve human participants or primary data collection. Institutional review board (IRB) approval was therefore not required.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"654"}}